[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641603":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":68,"collaborators":26,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":26,"enrollmentInfo":81,"targetDuration":26,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":101,"whyStopped":26,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Chonnam National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DAT (DOAC+clopidogrel) group","ACTIVE_COMPARATOR","Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.",[13],"Drug: DAT (DOAC+clopidogrel)",{"label":15,"type":16,"description":17,"interventionNames":18},"DOAC monotherapy group","EXPERIMENTAL","Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.",[19],"Drug: DOAC monotherapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","DAT (DOAC+clopidogrel)","Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"DOAC monotherapy","Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.",[15],[32],{"name":33,"affiliation":34,"role":35},"Young Joon Hong, MD, PhD","Chonnam National University","STUDY_CHAIR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Seung Hun Lee, MD, PhD","CONTACT","82-2-220-6246","lsh8602@naver.com",{"name":43,"role":39,"phone":40,"phoneExt":26,"email":44},"Joon Ho Ahn, MD, PhD","yhbky@naver.com",[46],{"facility":5,"status":26,"city":47,"state":47,"zip":48,"country":49,"countryCode":26,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Gwangju","61469","South Korea",{"type":51,"coordinates":52},"Point",[53,54],126.91556,35.15472,{"lat":54,"lon":53},[57,60,61,63,65,66],{"name":33,"role":39,"phone":58,"phoneExt":26,"email":59},"82-62-220-6246","hyj200@hanmail.net",{"name":38,"role":39,"phone":26,"phoneExt":26,"email":26},{"name":33,"role":62,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":38,"role":64,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"name":43,"role":64,"phone":26,"phoneExt":26,"email":26},{"name":67,"role":64,"phone":26,"phoneExt":26,"email":26},"Seok Oh, MD, PhD",{"type":62,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Young Joon Hong","Professor","100641603","abbreviated-antithrombotic-therapy-after-pci-in-patients-with-af-and-ami-100641603",false,"NCT07583784","Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI","Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction","HERO-AF-AMI","Inclusion Criteria:\n\n1. Patients aged 19 years old\n2. Patients with AF and CHA2DS2-VA score ≥2.\n3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)\n\n   * STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12\n   * NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12\n\n     1. Symptoms of ischemia.\n     2. New or presumed new significant ST-T wave changes\n     3. Development of pathological Q waves on electrocardiography.\n     4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n     5. Intracoronary thrombus detected on angiography.\n4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.\n\nExclusion Criteria:\n\n1. Patients contraindicated for use of DOACs or clopidogrel\n2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist\n3. Planned cardiac surgery within 1 year after randomization\n4. Patients with severe thrombocytopenia or coagulopathy\n5. Liver cirrhosis or severe hepatic dysfunction\n6. Advanced chronic kidney disease (creatinine clearance \\\u003C15 ml\u002Fmin\u002F1.73 m2) or on dialysis\n7. Prior history of intracranial hemorrhage\n8. Coexisting conditions related to high risk of life-threatening bleeding\n9. Pregnancy or breast feeding\n10. Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n11. Unwillingness or inability to comply with the procedures described in this protocol.","ALL","19 Years",{"count":82,"type":83},860,"ESTIMATED","INTERVENTIONAL",[86],"NA","The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).",[89,90,91,92],"Myocardial Infarction (MI)","ST-Segment Elevation Myocardial Infarction(STEMI)","NSTEMI - Non-ST-Segment Elevation Myocardial Infarction","AF - Atrial Fibrillation",[94,95,96,97,98,99,100],"AF","Myocardial infarction","STEMI","NSTEMI","DOAC","NOAC","OAC alone","NOT_YET_RECRUITING","2026-06-15",{"date":104,"type":105},"2026-06-17","ACTUAL",{"date":107,"type":83},"2026-07-01",{"date":109,"type":83},"2032-12-31",{"name":5,"class":6},1]